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Abstract 
 
One of the leading causes of death following traumatic injury is exsanguination. The 
body addresses bleeding through the process of hemostasis which includes the formation of a 
fibrin mesh structure that holds a blood clot together. During traumatic injury, hemostasis may 
be unable to stop excess bleeding. Fibrin based hemostatic agents have been developed, 
however, these studies often use fibrin obtained from biological sources, which poses risk of 
infection.  A novel amphiphilic peptide (h9e) has been studied to form three dimensional 
nanofibers networks.  In this research, we studied the ability to form a synthetically produced, 
fibrin-mimic, hemostatic material from the h9e peptide sequence. The objective of this study was 
to determine the blood gelation strength of the h9e peptide necessary to arrest bleeding in the 
Wistar Rat model.   
Commercial mouse blood was used for blood gelation in vitro studies. Dynamic 
rheometer was used to determine the gelation kinetics at varied h9e peptide concentrations 
ranging from 1-5% wt. By directly mixing the h9e peptide with blood, we observed that the 
blood gelation strength right after mixing increased as the h9e peptide weight % concentration 
increased, from 67 to 1086 Pascals in the peptide concentration from 1 to 5%, respectively. After 
24 hours, final gelation strength of all concentrations with commercial mouse blood was lower 
than the instantaneous strength but consistent throughout testing. Similar testing was conducted 
using commercial Wistar Rat blood with weight % concentrations of 1, 3, and 5% of h9e peptide. 
The gelation strength was 500, 1665, and 1914 Pascals, respectively. We also determined the 
gelation strength of Wistar Rat blood components, such as red blood cells, serum, and plasma 
  
with 1% h9e peptide. We observed the gelation response induced with individual blood 
components; however, the strength is weaker than whole blood.  
In vivo, we applied the cut-tail method by dipping the cut-tail of Wistar Rats into the h9e 
peptide solutions for 10 seconds and then took it out for blood lost collection. We observed that 
h9e peptide solution at 1, 3, and 5% weight concentrations can all generate hemostatic function.  
The h9e peptide solution at 5% weight concentration (1914 Pa) was able to outperform a 
commercial hemostatic material (Moore Medical CELOX* Hemostatic Granules), significantly 
reducing both bleeding time and blood lost: h9e peptide at 5% had a bleeding time of 94 sec and 
0.75 mL blood lost, while the Celox hemostatic granules had a bleeding time of 225 sec and 1.5 
mL blood lost.    
Transmission Electron Microscopy and Spinning Disk Confocal Microscope imaging 
indicated a blood component reinforced, web-like, h9e nanofiber structure similar to the structure 
formed by fibrin in a blood clot. This study showed that h9e peptide has the potential to be used 
to induce hemostasis. 
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Chapter 1 - Introduction and Literature Review 
1.1 Overview 
One of the leading causes of death following a traumatic injury is exsanguination [1-3]. 
Among U.S. military personnel, hemorrhage is one of the greatest threats to survival as most 
deaths related to combat injuries occur before military personnel have the opportunity to reach a 
medical facility [4-5]. Among American civilians, bleeding is the leading cause of death in 
operating rooms [6].  Extensive blood loss due to hemorrhage is also a worldwide concern.   
Because exsanguination is responsible for a large percentage of deaths, over the past 40 years, 
there has been a significant amount of research conducted. To address this issue, several 
hemostatic materials have been developed. 
 
1.2 Hemostasis 
The body naturally addresses the issue of bleeding by the process of hemostasis. 
Hemostasis is the formation of a blood clot at the wound site [7]. Hemostasis occurs in two 
phases: Primary and Secondary. During the primary phase of hemostasis, platelets adhere to the 
wound site. In damaged vascular tissue, platelets release chemical signals that initiate the second 
phase of hemostasis: The coagulation cascade. 
The coagulation cascade is a sequential activation of enzymes that proceeds through two 
enzymatic pathways: Intrinsic (contact activation) and extrinsic (tissue factor) [7-8]. The intrinsic 
pathway begins upon damage to endothelial tissue. It activates factor XII which activates a 
sequence of additional factors. This leads to the activation of factor X [8]. The extrinsic pathway 
is initiated at the site of the wound as a response to the exposure of tissue factor to blood [8]. 
This activates factor VII, leading to the step-wise activation of factor X. Both the intrinsic and 
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extrinsic pathways join at the activation of factor X, which is referred to as the common pathway 
(Figure 1.1). Factor X is a prothrombinase that cleaves prothrombin into thrombin. Thrombin 
then activates fibrinogen into fibrin. Fibrin then cross-links at the site of the wound, forming a 
web, which maintains the structure of the platelet plug, forming a blood clot [8]. Figure 1.2 
provides a visual schematic of the formation of a blood clot.   
  
1.3 Hemostatic Agents  
 Though the body has a process by which to address the issue of bleeding, during a 
traumatic injury, the body may be unable to stop or slow the amount of bleeding caused by the 
injury. When the body is unable to control the amount of blood lost, survival is threatened due to 
hemorrhaging and exsanguination may occur. To address these issues, several hemostatic agents, 
employing a variety of mechanisms, have been developed. Hemostatic agents stop bleeding by 
either their own mechanical methods or by reinforcing the coagulation cascade [7]. 
Hemostatic materials can be classified a number of different ways. Generally they are 
classified as either biologically based or synthetic. Biologically based materials are those derived 
directly from living organisms. Biologically based materials are effective in controlling 
hemorrhage but may pose a risk of infection if derived from a contaminated source [7,9]. 
Synthetic materials are those chemically derived from sources other than living organisms. 
Synthetic materials are also effective in controlling hemorrhage and do not pose a risk of 
infection. However, synthetic materials may not be designed to control hemorrhage in severe 
wounds [8]. Table 1.1 provides an overview of selected hemostatic materials and evaluates some 
of their strengths and weaknesses.  
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1.4 Biologically Based Hemostatic Agents 
1.4.1 Fibrin Based Materials 
 Toward the end of coagulation cascade, fibrinogen is converted to fibrin in the presence 
of thrombin. Fibrin is an insoluble, fibrillar protein, formed at the site of an injury in response to 
the induction of the coagulation cascade [10]. Fibrin is arranged in long chains that cross-link to 
form a mesh network. The fibrin mesh entraps platelets, forming a clot that prevents further 
blood loss [7, 10].  
 Fibrin based products are usually derived from either human or bovine thrombin found in 
blood plasma. Fibrin based products include two main components generally packaged in 
syringes:  One containing a fibrinogen suspension and one containing an activation solution 
(thrombin or calcium).  Fibrin based products are applied by releasing the contents of both 
syringes simultaneously, combining to form a fibrin matrix used to arrest bleeding when applied 
to the wound site [7, 11].  Fibrin adhesives can be applied as an aerosol spray or as a liquid fibrin 
glue. Some examples of fibrin sealants include Tisseel (Baxter International Incorporated, 
Deerfield, IL, USA), Beriplast P (CSL Behring, King of Prussia, PA, USA), and Evicel (Ethicon 
US, LLC, Somerville, NJ, USA). 
 Fibrin based products have some advantages over other products. Mainly, fibrin based 
products are fast acting and very effective due to the natural mechanical role of fibrin in the 
coagulation cascade. Fibrin based products are also biodegradable [7, 11]. There are also risks 
involved with Fibrin based products. They can be very expensive. Fibrin based products may 
also pose the risk of infection. Though plasma used for the formation of fibrin based products is 
screened for viruses, the risk of infection cannot be fully eliminated [7, 11]. 
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1.4.2 Thrombin based products 
At the start of the common pathway, activated factor X cleaves prothrombin into 
thrombin (Figure 1.1). Thrombin (activated factor II) is the pivotal enzyme within the 
coagulation cascade and is responsible for several functions. Thrombin activates several clotting 
factors and encourages platelet adhesion [12]. However, the main function of thrombin is to 
convert fibrinogen to fibrin.  
Thrombin based products are derived from one of three main sources: Bovine thrombin, 
human thrombin, or human recombinant thrombin. Bovine thrombin is obtained by extracting 
prothrombin from bovine plasma and activating it into thrombin [12]. Human thrombin is 
obtained by extraction from human plasma [12]. Human recombinant thrombin is obtained from 
recombinant DNA procedures performed on a genetically modified Chinese hamster ovary cell 
line [12-13].  Thrombin based products should be applied directly to the wound. Some examples 
of Thrombin based products include Thrombin-JMI (Pfizer Incorporated, Peapack, NJ, USA), 
Recothrom (ZymoGenetics Incorporated, Seattle, WA, USA), and Evithrom (Ethicon US, LLC, 
Somerville, NJ, USA).  
There are also a few combination products including Evicel (mentioned in the fibrin 
based materials section) and FloSeal (Baxter Healthcare Corporation, Deerfield, IL, USA). 
Evicel uses thrombin to activate fibrinogen into fibrin for hemostatic use. FloSeal is a gelatin 
matrix and thrombin combination product. FloSeal is composed of a thrombin component and a 
cross-linked gelatin [7, 14, 17]. The thrombin component activates the coagulation cascade while 
the matrix simultaneously serves as a sealant to stop bleeding [15].  
Thrombin based products have some advantages over other products. Mainly, thrombin 
based products are fast-acting, can be applied directly to the wound site, and are effective due to 
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the natural role of thrombin in the coagulation cascade [12,15,17]. Though thrombin based 
products have some advantages over other products, there are also risks involved. Thrombin 
based products may also pose the risk of immunological response, particularly those derived 
from bovine thrombin [7, 16]. Though all types of plasma used for the formation of thrombin 
based products are either screened for viruses, purified, or both, the risk of infection cannot be 
fully eliminated [7, 17]. 
 
1.4.3 Other Noteworthy Biologically Based Hemostatic Agents 
 While a majority of biologically based hemostatic materials include fibrin or thrombin 
components, there are a few additional types of biologically based hemostatic materials 
available, particularly BioGlue (CryoLife Incorporated, Kennesaw, GA, USA) and Vitagel, 
previously known as CoStasis (Stryker, Kalamazoo, MI, USA).  
 BioGlue is a bovine serum albumin and gluteraldehyde cross-linked adhesive. 
Glutaraldehyde molecules cross-link with bovine serum albumin molecules within the tip of the 
BioGlue applicator. BioGlue is then applied to the tissue surface and bind to surface proteins of 
the target tissue [7, 18]. BioGlue is an ideal material to seal the area around staples and sutures, 
requiring only a thin layer to reinforce the closure, to prevent excess bleeding [11, 19]. BioGlue’s 
main advantage over other biologically based hemostatic materials is its ability to function 
independently of the coagulation cascade [7, 18]. There are however a few drawbacks to using 
BioGlue. BioGlue must be applied to a dry surface [7, 18]. This may be very inconvenient as it 
may be difficult to keep a bleeding surface dry. It is also important to apply only a small amount 
of BioGlue as larger quantities of product may pool and lead to infection [19].   
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Vitagel is a combination of thrombin, fibrinogen, platelets, and microfibrillar collagen. 
Vitagel is supplied in a dual syringe with a mixing tip. One side of the syringe contains the 
microfibrillar collagen and thrombin component. The other side contains fibrinogen and platelets 
obtained from blood plasma extracted from the patient [20-21]. The components combine as they 
are released from the syringe and applied topically. The thrombin, fibrinogen, and platelet 
components promote hemostasis and initiate the coagulation cascade. 
Vitagel has few advantages over other hemostatic materials. Vitagel is derived from the 
patient’s own blood plasma. This eliminates the risk of infection from donor plasma sources 
[21]. The use of Vitagel has also been reported to reduce the need for blood transfusions after 
total knee arthroplasty [22]. While there are some advantages to the use of Vitagel, there are also 
several disadvantages. The use of the patient’s blood plasma requires the use of a centrifuge and 
thus requires some additional preparation prior to use. The thrombin in Vitagel is obtained from 
bovine sources. There is a risk of infection and immunological response with the use of bovine 
obtained products [20, 22]. Vitagel can also be expensive and the success of its use is dependent 
upon the experience of the individual applying it [23].  
 
1.5 Synthetic Hemostatic Agents    
1.5.1 Chitosan based hemostatic products 
 Chitin is a naturally occurring poly-N-acyl glucosamine found in arthropod shells [11, 
24]. When chitin reaches a certain percent of deacetylation, it becomes a chitosan polymer. 
Chitosan based products interact directly with red blood cells. Through electrostatic interactions, 
positively charged chitosan attracts negatively charged red blood cells and platelets, forming a 
cross-linked seal that is independent of natural blood clotting factors and the coagulation cascade 
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[2, 11, 24].  The most common chitosan based hemostatic materials are Celox (Medtrade 
Products LTD, Crewe, UK) and HemCon (HemCon Medical Technologies incorporated, 
Portland, OR, USA).  
Chitosan based products have several advantages over other hemostatic materials 
products. Chitosan based materials operate independently of the coagulation cascade. Because 
the body’s natural clotting factors are not involved, chitosan based products can clot heparinized 
blood [25].  Chitosan based products are biocompatible, as they are composed of glucosamine 
[25]. At a low pH, chitosan based products also have a polycationic nature and natural 
antibacterial properties [11, 23]. Though there are several advantages to using chitosan based 
products, chitosan based bandages (HemCon) may not fit properly on atypically shaped wounds 
and may need to be cut in order to fit [25]. This wastes valuable time and may not be possible 
during a traumatic situation.  
 
1.5.2 Mineral Zeolite based products  
 Zeolite is a natural mineral that is composed of a porous, crystalline structure [5, 11]. 
Mineral zeolite products induce hemostasis by promptly absorbing water when the zeolite 
material comes in contact with blood [2,5,11]. Water molecules are held within the material by 
hydrogen bonds.  The absorption of water leads to an increased concentration of natural blood 
coagulation elements, which assist in the rapid formation of a clot [2,5,11]. Currently QuikClot 
(Z-Medica, LLC, Wallingford, CT, USA)  is the primary mineral zeolite hemostatic material 
available. 
There are a few benefits to the use of QuikClot. QuikClot can be highly effective in low-
pressure bleeding wounds [23]. Quikclot is also easy to use and fairly inexpensive [11]. Though 
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there are several benefits to the use of QuikClot, there are also some drawbacks. QuikClot is not 
very effective in high-pressure bleeding situations [23]. In some instances, QuikClot induces an 
exothermic reaction that produces high temperatures [2,5,11]. Though the manufacturer has 
reformulated the product to address exothermic reaction concerns, the high temperatures 
produced by QuikClot may pose a significant burn risk and may require additional training in 
order to properly handle the material [2,5,11].  
 
1.5.3 Polyethylene Glycol Hydrogel Products 
 Polyethylene glycol hydrogel products are composed of two synthetic polyethylene 
glycol polymers, a hydrogen chloride solution, and a sodium phosphate/sodium carbonate 
solution [23, 27].  The primary Polyethylene glycol Hydorgel material is CoSeal (Baxter 
Healthcare Corporation, Deerfield, IL, USA). CoSeal crosslinks with proteins on the surface of 
the wounded tissue and forms a synthetic hydrogel seal [23, 26]. CoSeal was developed as a 
hemostatic material for use in cardiac and other thoracic procedures [26].  
There are some benefits associated with the use of CoSeal. The effectiveness of CoSeal is 
not dependent upon the participation of the coagulation cascade [26]. Without reliance on the 
coagulation cascade, CoSeal may be useful in patients with blood coagulation deficiencies [26]. 
CoSeal works rapidly and is not known to instigate an inflammation response [11, 23]. There are 
however, a few drawbacks to the use of CoSeal. CoSeal can swell up to four times its original 
volume within 24 hours [23, 27]. This may pose a problem if areas that may be negatively 
affected by excessive material swelling. CoSeal is not a versatile hemostatic material, as it was 
designed to specifically assist with cardiac and thoracic procedures.     
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1.6 Nanotechnology in Medicine  
The use of nanotechnology in the field of medicine has been rapidly increasing over the 
past few years. The main goal of research in nanotechnology is to construct novel materials on a 
nanoscale. In order to meet the changing demand for materials needed within the medical field, 
several research groups have begun working with nanomaterials.  
Protein nanotechnology has been used in the field of medicine for drug delivery, tissue 
engineering, 3-D cell culture, and scaffolds [28-30]. Proteins can be used as the structural 
framework for these nanomaterials [28].  Protein polymers are composed of chains of amino 
acids. Chains of amino acids, shorter then proteins, are called peptides. Peptides can be rationally 
designed and synthesized to serve a particular function, or to form desirable shapes, by several 
processes including, but not limited to, self-assembly.  
Self-assembly is a process by which weak interactions form reversible associations to 
achieve a structure that is energetically optimized [28]. Several molecules including DNA, 
proteins, and peptides, are known to self-assemble [28]. The process of self-assembly requires 
favorable thermodynamic conditions. These conditions can be directed by hydrogen bonding, 
dipole-dipole interactions, other electrostatic interactions and hydrophobic interactions [28]. The 
aforementioned interactions can result in several types of nanostructures, including a hydrogel.  
 
1.6.1 Peptide Hydrogels 
Peptide hydrogels are attractive for use in biomaterials. Because of their high water 
content and structural polymer framework, peptide hydrogels can be used for a variety of 
materials, including 3-D cell culture matrixes and injectable materials, without the loss of the 
molecule’s original biological function [29-32]. To use a peptide hydrogel as an injectable 
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material, it is beneficial if the peptide exhibits shear-thinning and rapid recovery characteristics 
[29]. Shear thinning hydrogels are a special type of material. The storage modulus of this type of 
hydrogel decreases rapidly under shear force but also rapidly recovers when left undisturbed 
[29]. Generally the self-assembly of an injectable hydrogel occurs under specific conditions. 
Sometimes these conditions involve a certain temperature or pH requirement [29]. A hydrogel 
forming peptide may be increasingly useful if, in addition to being injectable and shear thinning, 
the peptide can be injected into the body as a liquid solution and form a hydrogel triggered by a 
condition within the body such as pH, temperature, or concentration of a particular trigger 
substance [29].  
 
1.6.2 Peptide based hemostatic research 
There are several types of biological and synthetic hemostatic materials available to meet 
a variety of hemorrhage control needs. However, as previously mentioned, there are several 
drawbacks and unresolved issues. The use of self-assembling peptides has been investigated to 
serve as an alternative to current hemostatic materials and to address the shortcomings of 
previous hemostatic materials. Self-assembling peptides that possess the ability to form 
nanofibers and/or hydrogels have shown promise as use in wound healing and hemostasis [33-
34]. Peptide hydrogels offer several benefits over the preceding hemostatic agents, specifically, 
reduced risk of negative immune response, reduced risk of infection, and stable nanoweb 
structures that serve as a hemostatic seal.  To date, the ability of several peptide sequences to 
induce hemostasis has been studied. Though these studies appear to address the shortcomings of 
previous hemostatic materials, few, if any, have been approved for use by the US Food and Drug 
Administration.  Table 1.2 provides an overview of peptide based hemostatic materials.   
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1.6.3 N-Pro-Ser-Phe-Cys-Phe-Lys-Phe-Glu-Pro-C  
The N-Pro-Ser-Phe-Cys-Phe-Lys-Phe-Glu-Pro-C peptide is a sequence that forms a 
fishnet-like nanoweb at certain concentrations [33]. The sequence is amphiphilic because it 
contains the ionic residues Lys and Glu toward the C terminus and the non-ionic residues Phe, 
Cys,and Phe, toward the N terminus. Proline residues at both terminals to cause turns in the 
sequence that can be used for tethering peptide components together [33].  The N-Pro-Ser-Phe-
Cys-Phe-Lys-Phe-Glu-Pro-C peptide contains both β-sheet and β-turn structures [33]. The 
sequence also has self-healing abilities and it behaves as an elastic gel [33]. The exact 
mechanism used by the peptide sequence to stop bleeding appears to need additional research. 
 
1.6.4 KOD  
Collagen is a structural protein found in the connective tissue of mammals. In addition to 
providing structural support in the bodies of mammals, collagen also has the ability to activate 
the coagulation cascade. The KOD sequence was designed to mimic collagen. It is composed of 
36 amino acids, including a proline-hydroxyproline-glycine repeating sequence, similar to that of 
collagen [35]. The KOD sequence forms triple helix nanofibers. The triple helix nanofibers add 
end-to-end and can interweave into a hydrogel [35].   The KOD peptide is able to arrest bleeding 
by adhering to and activating platlets [35]. This induces the coagulation cascade in a similar 
manner as collagen.  
 
1.6.5 TDM-621 
 TDM-621 is a peptide that is composed of alternating hydrophilic aspartic acid, 
hydrophilic arginine, and hydrophobic alanine amino acid residues, chemically named acetyl-
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(arginyl-alanyl-aspartyl-alaninyl)4-amide [36]. The TDM-621 peptide forms a hydrogel with a 
collagen-like fibrous network at a pH of 7 in the presence of sodium and potassium ions [36]. 
When the acidic TDM-621 peptide solution comes in contact with blood, the solution is 
neutralized and the β-structure of the peptide forms fibers that assemble into a hydrogel [36]. The 
peptide hydrogel serves as a hemostatic plug, allowing for coagulation to occur [36].   
 
1.6.6 SPG-178 
Self-assembling peptide gel, amino sequence #178 (SPG-178) is a chemically 
synthesized peptide sequence composed of arginine (R), leucine (L), alanine (A), and aspartic 
acid (D) residues [37].  The SPG-178 peptide was designed to have an isoelectric point of 11.5 
so that stability in a neutral pH environment can be maintained [37]. In aqueous solution, the 
SPG-178 peptide has an antiparallel β-sheet structure. The SPG-178 self-assembles to form 
nanofibers that are less than 10 nm in diameter [37]. The nanofibers possess the ability to further 
form a stable net structure that covers the surface of a wound, thus controlling hemorrhage [37].  
 
1.6.7 IAP 
The IAP sequence is an amphipathic peptide composed of a series of repeating leucine 
(L) and lysine (K) residues (KLLKLL) [34]. The IAP peptide forms a helical structure with 
hydrophilic lysine residues on one side and hydrophobic leucine residues on the other [34]. It is 
believed that IAP facilitates hemostasis by accelerating several enzymatic functions within the 
coagulation cascade [34]. Though the exact mechanism used by IAP is still unknown, its 
hemostatic properties are likely due to its amphipathic nature and helical structure [34].  The IAP 
peptide sequence can be combined with certain biocompatible hydrogels. Because hydrogels 
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absorb large amounts of water and possess the ability to conform to atypically shaped wounds, 
the hemostatic functions of the IAP peptide can be increased [34].   
 
1.6.8 EAK-16 
 EAK-16 is a peptide sequence that is derived from a segment of the Z-DNA binding 
yeast protein, Zuotin [38]. There are several derivatives of EAK-16 peptides being studied for 
the hemostatic properties. In general the types of EAK-16 peptides being studies have the same 
amino acid composition but are arranged into different amino acid sequences [39]. EAK-16 
peptides are generally self-assembling and possess the ability to form nanofibers. EAK-16 
nanofibers form net-like scaffolds. It is suspected that ions and coagulation factors absorbed by 
EAK-16 peptides contribute to their ability to rapidly control hemorrhage [38]. It is important to 
note however, that different types of EAK-16 peptides may possess different properties [39].  
 
1.6.9 RADA16 
One of the most widely researched peptide sequences is RADA16. The RADA16 peptide 
consists of alternating hydrophobic alanine (A), and hydrophilic arginine (R) or aspartic acid (D) 
residues (AcN-RADARADARADARADA-CONH2) [38, 40-41]. In an aqueous environment, 
the RADA16 peptide forms a stable β-sheet structure and nanofibers [40]. At neutral pH, the 
RADA16 peptide self-assembles into a hydrogel scaffold. It is believed that the RADA16 peptide 
induces hemostasis when it reacts with ions present in the blood [41]. However, the exact 
mechanism for hemostasis is not fully understood [42].  The RADA16 peptide has been found to 
be biodegradable and can be absorbed by the body [40].   RADA16 hydrogel is also able to 
control hemorrhage in a-typically shaped wounds [40]. Several modified versions of the original 
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RADA16 peptide sequence have been studied. Some of them appear to be just as effective as the 
original RADA16 sequence at controlling hemorrhage [40].  
 
1.7 Peptide Sequence Development within the Bio-Materials and Technology Lab in the 
Department of Grain Science at Kansas State University 
 
The Biomaterials and Technology lab in the department of Grain Science and Industry at 
Kansas State University has identified two unique peptide sequences, h9 and eD2, that possess 
similar qualities as the previously mentioned peptide sequences.  
The h9 peptide sequence (FLIVIGSII), was derived from a subunit of human muscle L-
type calcium channel [28]. The h9 peptide sequence exhibits a high hydrophobicity and can form 
a β-like structure, by self-assembly [28]. The h9 peptide also forms a viscous gel-like substance 
when mixed at certain concentrations [28].  
The eD2 peptide sequence was designed from a combination of spider flagelliform silk 
protein and the Ca
+
 binding portion of Lipase Lip A from Serratia marcescens, a species of gram 
positive, rod-shaped bacteria [31].  
The spider flagelliform silk sequence (GPGGX; where X represents any amino acid) was 
selected because it forms a β-spiral motif that provides the elasticity in the high tensile strength 
in spider silk [31]. Each amino acid provides specific properties of the sequence. The Glycine 
(G) provides flexibility. The Proline (P) influences mechanical properties and structure by 
affecting cross-linking and hydrogen bonding [31].  
The Ca
+
 binding portion of Lipase Lip A from Serratia marcescens sequence 
(GXGXDXUX; where X represents any amino acid and U represents any hydrophobic amino 
acid) was selected for its calcium binding ability. As in the spider silk sequence, individual 
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amino acids provide specific properties to the sequence. Namely the Aspartate (D) is necessary 
to facilitate ion bonding [31].  
The eD2 sequence (GPGGDGPGGD) was formed by rationally combining the two 
aforementioned sequences through a process of “hiding” the sequences in each other [31]. The 
sequences were “hidden” by substituting unnecessary amino acids such that the new sequence 
retained vital properties of both of the parent peptide sequences [31].  
The eD2 peptide sequence is self-assembling, forms a β-spiral structure in an aqueous 
environment, and forms nanofibers triggered by the addition of Ca
+
 [31].  
 
1.7.1 h9e peptide sequence development 
The h9e peptide sequence was designed by rationally combining the hydrophobic h9 
sequence and the hydrophilic eD2 sequence [29]. The novel h9e peptide sequence contains 
several physical properties that are considered ideal for peptides developed for use in 
nanotechnology. The h9e peptide sequence is amphiphilic due to its hydrophobic and hydrophilic 
segments [29]. The h9e peptide has a helical structure with the C-terminal amino acids bent into 
the structure [43]. The nanofibers formed by h9e are about 5nm in diameter without a specific 
orderly shape [43]. When Ca
+
 is added to h9e peptide solution, nanofibers rapidly assemble into 
a peptide hydrogel matrix [43]. The hydrogel formed by h9e is both shear-thinning and 
recoverable [29, 43].  
To date, the h9e peptide has been successfully used for a variety of applications including 
as an influenza H1N1 vaccine adjuvant, a 3-D cell culture material for drug testing, and as an 
adjuvant for modified live virus vaccines [29-30, 32]. The success of the h9e peptide sequence in 
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these applications, along with favorable physiological properties, indicates the h9e peptide 
sequence may be a useful component in other biomaterials within the field of medicine. 
 
1.8 Objectives 
 The main objective of this study was to determine the blood gelation strength of the h9e 
peptide necessary to arrest bleeding in the Wistar Rat model. Specific objectives were to: (1) 
study the gelation kinetics of h9e peptide solution with commercial mouse blood, commercial rat 
blood, and commercial rat blood components using the Dynamic Rheometer; (2) conduct 
hemostatic efficiency study with Wistar rat model and compare to a commercial hemostatic 
agent.  
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Table 1.1 Selected Hemostatic Agents 
Hemostatic 
Material 
Material 
Type 
Mechanism Advantages Disadvantages Examples 
Fibrin Based 
Materials 
Biological Cross-links to 
form a matrix that 
supports clotting 
factors 
[7, 10].
 
Effective, Fast 
acting, takes 
advantage of 
natural 
coagulation 
cascade and 
Biodegradable 
[7, 
11].
  
Can be expensive 
and Risk of 
infection if 
derived from 
contaminated 
sources 
[7,11].
 
Tisseel, 
Beriplast P 
and Evicel.  
Thrombin Based 
Materials 
Biological Activates the 
coagulation 
cascade,  forming 
a hemostatic plug 
Effective, fast 
acting, can be 
applied directly 
to the wound, 
and takes 
advantage of 
natural 
coagulation 
cascade process 
[12-14, 16].
 
Can be expensive, 
Risk of 
immunological 
response, and 
Risk of infection 
if derived from 
contaminated 
sources
 [12-13, 16].
 
Thrombin-JMI, 
Recothrom, 
Evithrom, and 
Evicel.  
Bovine Serum 
Albumin and 
Gluteraldehyde 
Biological  Glutaraldehyde 
cross-links with 
bovine serum 
albumin and 
creates an 
adhesive that and 
binds to surface 
proteins of target 
tissue 
[7,18].
  
Ideal for sealing 
area around 
sutures and 
staples, only 
requires thin 
layer, and 
functions 
independently of 
coagulation 
cascade 
[7,11,18-19].
 
Requires dry 
surface, large 
amounts of 
product may pool 
and lead to 
infection 
[7, 18-19].
 
BioGlue 
Platelet based 
Sealant 
Biological Thrombin, 
fibrinogen, 
platelets, and 
microfibrillar 
collagen combine 
and initiate the 
Derived from 
patient’s own 
plasma (no donor 
source) providing 
reduced risk of 
infection and 
Requires 
centrifuge, Risk 
of infection and 
immunological 
response from 
bovine obtained 
Vitagel 
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coagulation 
cascade  
may reduce need 
for blood 
transfusions in 
certain cases 
[21-
22].
 
components, can 
be expensive, and 
may require 
experience to 
handle 
[20, 22-23]
 
Chitosan Based 
Hemostatic 
Products 
Synthetic Attracts red blood 
cells and platelets 
to form a cross-
linked seal 
[2, 11, 
24].
 
Functions 
independently of 
Coagulation 
cascade, can clot 
heparinized 
blood, 
biocompatible, 
and some 
antibacterial 
properties 
[11, 23, 
25].
 
Bandages may not 
fit atypically 
shaped wounds 
[25].
 
Celox and 
HemCon 
Mineral Zeolite 
Based Products 
Synthetic Absorbs water 
concentrating 
blood coagulation 
elements 
[2, 5, 11].  
 
Highly effective 
in low-pressure 
bleeding wounds, 
easy to use, and 
inexpensive 
[11, 
23].
    
Not very effective 
in High pressure 
bleeding wounds, 
exothermic 
reaction that leads 
to burn risk, may 
require special 
training to handle 
[2, 5, 11].
 
QuikClot 
Polyethylene 
Glycol Hydrogel 
Products 
Synthetic Crosslinks with 
proteins on 
surface of target 
tissue and forms a 
synthetic 
hydrogel seal 
[23, 
26].
  
Functions 
independently of 
Coagulation 
cascade, may 
work in patients 
with blood 
coagulation 
deficiencies, and 
is not known to 
instigate 
inflammation 
response 
[11, 23, 26]. 
 
Can swell up to 4 
times its orginial 
volume within 24 
hours and 
designed 
specifically for 
cardiac and 
thoracic 
procedures 
[23, 27]. 
 
CoSeal 
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Table 1.2 Peptide based hemostatic materials 
Peptide Sequence Mechanism Notes 
N-Pro-Ser-Phe-
Cys-Phe-Lys-
Phe-Glu-Pro-C  
N-Pro-Ser-Phe-Cys-Phe-
Lys-Phe-Glu-Pro-C  
Unknown Amphiphilic; May work 
faster than chitosan on liver 
cut rat model; mechanism 
unknown 
KOD 36 residues; Proline-
hydroxyproline-glycine 
(repeating) 
Adheres to and activates 
platelets 
Collagen mimic; Induces 
coagulation cascade 
TDM-621 Aspartic acid, arginine, 
alanine (repeating) 
Forms hydrogel and 
serves as hemostatic plug 
Alternating hydrophobic 
and hydrophilic residues; 
Forms hemostatic plug 
SPG-178 Arginine, leucine, 
alanine, aspartic acid 
residues 
Forms nanofibers web to 
cover wound surface 
------ 
IAP Repeating Leucine and 
Lysine residues (KLLKLL) 
Unknown; Possibly 
accelerates enzymatic 
functions of coagulation 
cascade 
Helical structure with 
hydrophilic lysine on one 
side and hydrophobic 
leucine on the other; can 
conform to atypically 
shaped wounds 
EAK-16 Derived from Z-DNA 
binding yeast protein, 
Zuotin 
Ions and coagulation 
factors absorbed by EAK-
16 peptides contribute to 
rapid hemorrhage control 
Multiple types of EAK-16 
peptides; Self-assembling; 
form nanofibers 
RADA
16
 (AcN-
RADARADARADARADA-
CONH
2
)  
Unknown; Reacts with 
ions in blood 
Biodegradable; conforms to 
atypically shaped wounds;  
Several Variations of 
RADA
16 
peptide 
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Figure 1.1 Schematic of the Coagulation Cascade (adapted from Behrens et al.) [8]. 
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Figure 1.2 Schematic of blood clot formation  
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Chapter 2 - Hemostatic Efficiency of the h9e Peptide in Wistar Rats 
2.1 Introduction 
One of the leading causes of death following a traumatic injury is exsanguination [1-3]. 
Among U.S. military personnel, hemorrhage is one of the greatest threats to survival [4-5]. Most 
deaths related to combat injuries occur before military personnel have the opportunity to reach a 
medical facility [4]. A vast majority of exsanguination deaths are due to injuries to the torso area, 
where it may be difficult to control bleeding in a timely fashion [4,6]. Among American 
civilians, bleeding is the leading cause of death in operating rooms [7]. Extensive blood loss due 
to hemorrhage is a worldwide concern.   
In order to prevent or significantly reduce the number of deaths associated with 
exsanguination, research has been conducted over the past 40 years. The body naturally 
addresses the issue of bleeding by the process of hemostasis (coagulation cascade) [8]. However, 
during a traumatic injury, the body may be unable to stop or slow the amount of bleeding caused 
by the injury. To address these issues, several hemostatic agents have been developed. 
Hemostatic agents stop bleeding by either their own mechanical methods or by 
reinforcing the coagulation cascade [8]. Traditionally, medical personnel have used gauze and 
pressure to assist with the body’s natural process of hemostasis. Aside from the traditional gauze 
and pressure method, there are several types of hemostatic agents that are currently used to 
address medical needs. All of the hemostatic agents currently on the market offer their own set of 
benefits over other types. Therefore, it is usually necessary to select a hemostatic agent for use 
on a case by case basis. Though all hemostatic agents offer benefits, there are several 
unaddressed risks involved with hemostatic agent use.  
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Currently a majority of the hemostatic agents available on the market are derived from 
biological sources including purified bovine serum albumin, bovine thrombin, and crustacean 
chitin [8]. Because the components of these hemostatic agents are obtained from biological 
sources, the risk of allergic reaction or infection from contaminated biological systems is a 
concern [8,9].  
Recently self-assembling peptide sequences have been suggested for use as alternative 
biomedical materials [10].  Self-Assembling peptides that possess the ability to form nanofibers 
and hydrogels have shown promise for use in wound healing and hemostasis [11-12]. Peptide 
hydrogels offer several benefits over the preceding hemostatic agents, specifically, reduced risk 
of negative immune response and infection. 
Within the past few years, the Bio-Materials and Technology Lab, in the Department of 
Grain Science and Industry, at Kansas State University has developed a new amphiphilic peptide 
sequence, the h9e peptide. The sequence was produced by rationally combining two native 
peptide sequences, h9 and eD2, after comparing their primary functions. The h9 peptide sequence 
(FLIVIGSII), was derived from a subunit of human muscle L-type calcium channel [13]. The h9 
peptide sequence exhibits a high hydrophobicity and can form a β-like structure, by self-
assembly [13]. The h9 peptide also forms a viscous gel-like substance when mixed at certain 
concentrations [13].   
The eD2 sequence (GPGGDGPGGD) was formed by rationally combining a sequence of 
spider flagelliform silk protein and the Ca
+
 binding portion of Lipase Lip A from Serratia 
marcescens. The sequences were combined through a process of “hiding” the sequences in each 
other [14]. The sequences were “hidden” by substituting unnecessary amino acids such that the 
new sequence retained vital properties of both of the parent peptide sequences [14]. The eD2 
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peptide sequence is self-assembling, forms a β-spiral structure in an aqueous environment, and 
forms nanofibers triggered by the addition of Ca
+
 [14].  
The conformation, morphology, and mechanical properties of the h9e peptide have been 
studied extensively [14-15]. The h9e peptide has proven to be a useful as an adjuvant for both the 
influenza H1N1 vaccine and the porcine reproductive and respiratory syndrome virus vaccine 
[16-17].  The h9e peptide hydrogel proved to be biologically safe and performed 70% better than 
a commercial adjuvant [16]. It has also been shown that the h9e peptide has the potential to be 
used as a 3D cell culture matrix for drug testing [18].    
While exploring the many possible applications of this innovative peptide, it was 
determined that if mixed with serum albumin, a hydrogel would form. Hydrogels have the 
potential to be used for several applications including, but not limited to, the formation of a 
hemostatic agent. Because of its elasticity and high tensile strength properties, the h9e peptide 
hydrogel has the potential for use in biomaterials for medical uses and possibly the formation of 
a hemostatic agent. 
The main objective of this study was to determine the blood gelation strength of the h9e 
peptide necessary to arrest bleeding in the Wistar Rat model.  
 
2.2 Materials and Methods 
Preparation of h9e peptide solution 
H9e peptide was synthesized at the Bio-Materials and Technology Lab, in the 
Department of Grain Science and Industry at Kansas State University. After synthesis the peptide 
was cleaved, washed with anhydrous ether, dissolved in acetonitrile and distilled water (1:1 
ratio), frozen at -80°C, and freeze dried. Stock solutions of peptide were made by dissolving 
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freeze-dried peptide in 100mM NaHCO3 to the appropriate weight percentage. All solutions 
were autoclaved before use. The purity of the h9e peptide used was ≥ 85% confirmed by high 
performance liquid chromatography (HPLC).  
 
Rheological analysis of commercial mouse blood gelation  
A time sweep was conducted on h9e peptide solution and commercial mouse blood at the 
following wt % concentrations of h9e peptide dissolved in 100mM sodium bicarbonate: 1%, 2%, 
3%, 4%, and 5%. Equal volumes of the appropriate wt% of h9e peptide solution and commercial 
mouse blood (Innovative research, Novi, Michigan, USA) were combined in a microcentrifuge 
tube. The mixture was homogenized and either immediately added to the rheometer for 
evaluation or placed in a carbon dioxide incubator at 37°C for 24 hours (Nuaire, Plymouth, MN, 
United States). Samples placed in the incubator were removed after 24 hours and were added to 
the rheometer for evaluation. The elastic modulus, G’, of the h9e/blood hydrogel was determined 
using a C-VOR 150 rheometer (Malvern Instruments, Malvern, Worcestershire, United 
Kingdom). A plate 20mm in diameter was used with 1 % strain and frequency of 1 Hz at a 37°C 
temperature for 30 minutes.  
 
In vivo Hemostatic Efficiency in Rat Model 
Similar to the method used by Mortazavi et al., in this study 30 rats were divided 
randomly into 5 groups of 6 animals each [5]. Figure 2.1 shows the schematic for the in vivo 
experiment. Male Wistar rats were maintained on an AIN-93 pellet diet with free access to food 
and water, under 12-h light-dark cycles, for one week. Before excising the tail, rats were first 
anesthetized and maintained with 3% isoflurane (Figure 2.1 A) until the eyelid closure reflex was 
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lost and there was no reactive reflex in response to a toe pinch. In order to maintain an 
appropriate body temperature during anesthesia, a circulating water blanket was used at a 
temperature of 41-43°C (Figure 2.1. B). Following anesthesia, animals' tails were cut off at a 
thickness of 5 mm (Figure 2.1. C) using a pair of mortuary scissors. The cut tail was immediately 
inserted into a small vial containing the appropriate treatment (Figure 2.1. D). The 1st group 
received topical saline solution (negative control) and the 2
nd
 to 4
th 
groups received topical h9e 
peptide solution at 1, 3, or 5 wt%, respectively. The 5
th
 group received an application of a 
commercially available hemostatic agent as a positive control (Moore Medical CELOX* 
Hemostatic Granules). After treatment with the above mentioned agents, the volume of blood 
lost was measured using a scaled test-tube. The bleeding time was measured using a stop watch. 
Before the procedure was performed, the weight of each animal was recorded. The mean weight 
of animals used in each testing group was also recorded before the start of the procedure. In an 
attempt to be as accurate as possible, animals used were chosen at random. At the conclusion of 
the study, the rats were sacrificed using a carbon dioxide chamber. All animal testing was done 
in accordance to procedures approved by the Institutional Animal Care and Use Committee 
(IACUC protocol #3276). Statistical analysis of rat clinical trial data was performed using one-
way ANOVA. P-values of less than 0.05 were considered statistically significant. There was no 
significant difference in body weight variance between the treatment groups.  
 
Rheological analysis of instantaneous gelation of whole rat blood and blood components 
A time sweep was conducted on h9e peptide solution and Wistar rat blood components 
(red blood cells, blood plasma, or blood serum). H9e peptide was dissolved in 100mM sodium 
bicarbonate to yield desired wt% concentration according the aforementioned methods. Equal 
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volumes of the appropriate wt% of h9e peptide solution and whole wistar rat blood or the 
appropriate wistar rat blood component (Innovative research, Novi, Michigan, USA) were 
combined in a microcentrifuge tube. The mixture was homogenized and immediately added to 
the rheometer for evaluation. The elastic modulus, G’, of the h9e/blood hydrogel was determined 
using a C-VOR 150 rheometer (Malvern Instruments, Malvern, Worcestershire, United 
Kingdom). A plate 20mm in diameter was used with 1 % strain and frequency of 1 Hz at a 37°C 
temperature for 30 minutes.  
 
Transmission electron microscopy (TEM) 
The morphology of Rat blood and h9e solution was observed using transmission electron 
microscopy (TEM). Exactly six mL of the appropriate sample was placed onto a negative glow 
discharged carbon-coated copper grid for two minutes. The remaining sample was removed by 
blotting with a kimwipe (Kimberly Clark Professional, Roswell, Georgia, USA). The grid was 
then placed into 2% uranyl acetate for two minutes. Extra stain was removed by blotting with 
tissue paper. The wet grids were allowed to air-dry for several minutes prior to being examined 
under TEM. 
Samples were imaged using a FEI Technai G2transmission electron microscope at an 
electron acceleration voltage of 200 KeV. Images were captured using a standardized, normative 
electron dose and a constant defocus value from the carbon-coated surfaces. The images 
presented are presented in the absence of any further processing or image filtering. 
 
Spinning Disk Confocal Microscope 
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Ten µl of the appropriate sample was placed onto a glass slide and covered with a cover 
slip. The sample was observed under Olympus spinning disk confocal inverted microscope and 
images were captured by using slide book version 5.5 (3i-Intelligent Imaging Innovations, Inc.). 
 
2.3 Results  
Rheological analysis of commercial mouse blood gelation  
All weight % concentrations of h9e peptide tested induced a gelation response in 
commercial mouse blood. The gelation strength of the instantaneous samples increased as both 
time and weight % concentration of the h9e peptide increased (Fig. 2.2). With the exception of 
the 1% wt concentration, all other % wt concentrations were above 100 Pa within 1-3 seconds. 
The 1% wt concentration reached the 100 Pa level after about 10 minutes.  
Compared to the instantaneous samples, the gelation strength of all concentrations 
decreased when allowed to sit 24 hours post homogenization (Fig. 2.3). Similar to the 
instantaneous samples, as the % concentration of h9e solution increased, the gelation strength 
increased.  
 
In vivo Hemostatic Efficiency of h9e Peptide Solution in Rat Model 
In order to observe the ability of h9e solution to control hemorrhage in a live, bleeding 
model, in vivo testing was conducted. The hemostatic efficiency test showed that all percent 
concentrations of h9e peptide solution were effective in controlling hemorrhage in comparison to 
the sterile saline negative control (Table 2.1). Though all concentrations of h9e solution were 
effective in reducing blood lost, the 5% h9e solution was able to control bleeding most 
effectively. The 5% h9e peptide solution outperformed the commercial positive control Celox™ 
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granules, reducing both bleeding time and blood lost.  Similar to the results obtained by the 
rheology studies, as the concentration of h9e solution increases, the hemostatic efficiency also 
increases.  
 
Rheological analysis of instantaneous gelation of whole rat blood and blood components 
The rheological analysis of commercial rat blood was used to compare gelation strength 
to that of the commercial mouse blood.  Similar to the commercial mouse blood, the gelation 
strength increased as both time and concentration of the h9e peptide increased (Fig. 2.4).  
To further investigate the ability of 1% h9e to induce a gelation response when mixed 
with rat blood, rheological analysis of individual blood components (red blood cells, serum and 
plasma) was conducted. Figure 2.5 shows that a gelation response is induced with all three 
components tested, though the gelation strength of the blood serum with 1% h9e solution is 
much lower than the gelation strength of the red blood cells and blood plasma with 1% h9e 
solution.  
 
Transmission electron microscopy (TEM) 
 TEM imaging indicates that observed h9e nanofibers have a width of about 10 nm. TEM 
evaluation of both blood plasma and blood serum showed few significant differences (Figures 
2.7 and 2.8). Both the blood plasma and blood serum show aggregation of blood proteins and 
other components into agglomerate clusters.  TEM evaluation of 0.5% h9e with blood serum 
clearly illustrates the binding of blood serum components to the h9e fibers within the samples 
(Figure 2.9). TEM evaluation of 0.5% h9e with blood plasma indicates a similar binding of 
plasma components to the h9e fibers (Figure 2.10).  
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Spinning Disk Confocal Microscope 
 Confocal imaging of red blood cells only, in Figure 2.11, illustrates the red blood cells 
suspended freely in saline. When red blood cells are added to 0.5% h9e peptide solution, as in 
Figures 2.12 and 2.13, the cells become trapped within the h9e fiber nanoweb. The arrows within 
the images indicate the immobilized cells within the nanoweb compared to several cells floating 
freely in the background.  
 
2.4 Discussion  
This study is the first report of the h9e peptide’s ability to induce hemostasis. Similar to 
other peptide sequences used for hemostasis, the h9e peptide possesses characteristics that offer 
several advantages over biologically derived hemostatic agents. The h9e peptide sequence is 
amphiphilic. Amphipilicity as a physiochemical property has been known to induce hemostatic 
response by activating some of blood’s natural clotting factors [12]. The h9e peptide self-
assembles into nanofibers that have the ability to form a nanoweb structure. Nano web-like 
structures have been known to seal bleeding surfaces preventing hemorrhage and rapidly 
inducing hemostasis [19-20]. Nano web-like structures have also been known to be efficient in a 
typically shaped wounds [12]. The h9e peptide sequence contains no biological elements. The 
lack of biological elements eliminates the risk of infection from contaminated biological sources 
[19, 21].  
The h9e peptide induces hemostasis by forming a nano-web structure in the presence of 
blood. The h9e fibers are reinforced by components within the blood plasma and blood serum, as 
shown in TEM images. Red blood cells are entangled in h9e fibers, as shown in confocal images. 
Collectively, this causes a strong gelation response and the formation of a structure similar to 
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that of a blood clot. The aforementioned structure is then acts as both a preliminary thrombus 
and a surface upon which a thrombus can continue to develop until bleeding is arrested. The 
nano-web structure formed by the h9e peptide is similar to that of fibrin within the coagulation 
cascade. The h9e peptide sequence seems to mimic fibrin in its ability to maintain a blood clot 
structure.   
The success of the h9e peptide was confirmed in vivo. We used the tail-clip method in a 
Wistar Rat because it is easy to obtain reproducible results. In general, as the weight % 
concentration of h9e peptide solution increased, the hemostatic efficiency increased. Other 
peptide studies have been determined that higher peptide concentration may be beneficial to 
nanoweb formation [20].  
Despite the decreasing amount of blood lost, from low concentration to high 
concentration of h9e solution used, the 3% h9e solution had a slightly increased time of 
hemostasis induction compared to the 1% h9e solution (Table 2.1). There are two factors that 
may have contributed to this observation. The first is that the time recorded for all treatment 
groups was based on the visual judgment that bleeding in the wound had stopped. Though we 
were consistent with each animal tested, visual judgment is never flawlessly accurate. The 
second is that the animals used in the 1% h9e solution testing group weighed less than the 
animals used in the 3% h9e solution testing group (Table 2.1).  To be as accurate as possible, 
animals were randomized and statistical analysis showed there was no significant difference in 
weight between animal treatment groups.  
The 5% h9e solution induces the process of hemostasis much faster than the commercial 
Celox™ granules. On advertised packaging, Celox granules boast the ability to induce 
hemostasis in the presence of an anticoagulant. This claim has been confirmed by an 
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experimental study performed by Koksal et al [22]. In their study, they found that Celox induces 
hemostasis in the presence of a warfarin anticoagulant. Warfarin is an orally administered 
anticoagulant used to prevent thrombosis. Their study also indicates that Celox has the ability to 
clot blood under hypothermic conditions [22].  
The blood samples used in this study were drawn using Alsevers, a balanced isotonic salt 
solution, as an anticoagulant. Though the rats used in our study were not being treated with an 
oral anticoagulant, because the rheology data demonstrated that h9e peptide solution forms a 
stable hydrogel with the commercial blood, we speculate that h9e may also be able to induce 
hemostasis in the presence of an anticoagulant. Further clinical trials would be needed to confirm 
this theory. If our speculation is correct, this may prove significant in treating patients on blood 
thinners or possibly treating patients with blood clotting disorders.  
As mentioned before, high % concentrations of h9e peptide solution induced a faster 
hemostatic response. With the commercial mouse blood testing, it is important to note that the 
points plotted on the instantaneous gelation graph are not parallel with the X-axis. This indicates 
that if the assay were allowed to continue to run after the allotted 30 minutes, the Pa strength of 
the sample may still increase. The samples allowed to sit for 24 hours indicated decreased 
gelation strength in comparison to the instantaneous gelatinization results. The points plotted on 
the 24 hour gelation study graph are more parallel with the X axis. This indicates that within 24 
hours the samples may have reached a stable and homogeneous Pascal strength by sitting 
undisturbed.  This particular aspect of the study is vital to future uses of the h9e peptide as it 
would be undesirable for the hydrogel to weaken or become unstable within a short period of 
time.  
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Consistent with the commercial whole mouse blood rheological examination, the points 
plotted on the whole rat blood graph are not parallel with the X axis. This indicates that if the 
assay were allowed to continue, the gelation strength of those samples would also increase. 
Overall, the gelation strength of the rat blood samples was significantly higher than that of the 
mouse blood samples. This is probably due to a difference in blood protein and clotting factor 
between the two species.  
Previous research indicated that h9e forms a hydrogel when triggered by bovine serum 
albumin. It is well knows that albumin is abundant in whole blood and it is, therefore rational 
that blood components would contain some level of albumin and trigger a similar gelation 
response.  
The gelation strength of the red blood cell and blood plasma samples was significantly 
higher than that of the blood serum sample. It is well known that blood serum is obtained by 
intentionally removing the body’s natural clotting factors from blood plasma. The absence of 
clotting factors may be the cause of the reduced the gelation strength of the blood serum sample. 
Though all blood components tested triggered a gelation response, the reduced gelation strength 
of the blood serum sample may indicate that clotting factors play a role in h9e’s ability to induce 
hemostasis. The gelation response of all blood components was also lower than that of the 1% 
whole rat blood observed in Figure 2.4. This may indicate that each blood component plays a 
role in the gelation response and their interactions are interdependent.  
 
2.5 Conclusions 
We have demonstrated the h9e peptide’s ability to induce hemostasis in the Wistar Rat 
model by mimicking fibrin’s ability to provide the framework for a blood clot. Both the bleeding 
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time and amount of blood lost were lower than that of commercial Celox™ granules with the 5% 
h9e peptide solution. The h9e peptide is amphiphilic, nano-web forming, and contains no 
biological elements that may induce an immunological response or cause infection. Based on 
these findings, we consider the h9e peptide a useful component of a hemostatic material.  
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Table 2.1 Measured values of average animal body weight, blood lost, and total bleeding time 
 
Test Group Animal Body weight 
±SD (grams) 
Blood Lost ± SD 
(mL) 
Bleeding Time ± SD 
(seconds) 
Saline (Negative 
Control) 
245.85 ± 10.36 2.76 ± 0.66 521.33 ± 54.67 
1% h9e solution 239.33 ± 12.22 2.20 ± 0.81 203.33 ± 57.39 
3% h9e solution 252.05 ± 9.42 1.87 ± 0.90 226.00 ± 58.79 
5% h9e solution 253.45 ± 17.39 0.75 ± 0.29 94.00 ± 37.05 
Celox™ (Positive 
Control) 
254.91 ± 14.31 1.53 ± 0.87 225.20 ± 56.21 
 P= 0.24 P= 0.001 P= 7.18 x 10^-12 
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Figure 2.1 Scheme procedure of the in vivo experiment 
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Figure 2.2 Storage modulus vs time of mouse whole blood samples with various h9e peptide 
concentrations mixed and measured instantaneously 
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Figure 2.3 Storage modulus vs time of mouse whole blood samples with various h9e peptide 
concentrations mixed and measured 24 hours post gelation 
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Figure 2.4 Storage modulus vs time of rat whole blood samples with various h9e peptide 
concentrations mixed and measured instantaneously 
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Figure 2.5 Storage modulus vs time of rat blood components with 1% h9e peptide solution mixed 
and measured instantaneously 
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Figure 2.6 TEM imaging of 0.5% h9e peptide solution 
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Figure 2.7 TEM imaging of rat blood serum 
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Figure 2.8 TEM imaging of rat blood plasma 
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Figure 2.9 TEM imaging of 0.5% h9e with blood serum 
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Figure 2.10 TEM imaging of 0.5% h9e with blood plasma 
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Figure 2.11 Confocal imaging of untreated red blood cells 
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Figure 2.12 Confocal imaging of red blood cells with 0.5% h9e solution (1:2 cells to h9e) 
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Figure 2.13 Confocal imaging of red blood cells with 0.5% h9e solution (1:2 cells to h9e) higher 
magnification 
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Chapter 3 - Effects of antibiotics on hemostatic efficiency  
3.1 Introduction 
 It is generally accepted that all wounds have some type of bacteria growth but over 
colonization can prevent wound healing and cause chronic infection [1]. It is well known that in 
addition to controlling hemorrhage, preventing chronic infection is key to healing [1]. 
This work is our first report of the h9e peptide’s ability to form a stable hydrogel that can be 
used effectively for hemostasis. We have conducted preliminary research in an attempt to 
address the issue of chronic infection as well as hemorrhage. We have identified two potential 
additions to the h9e peptide solution for the purpose of producing an anti-bacterial hemostatic 
agent: Ampicillin and Neomycin Sulfate.  
 
3.2 Materials and Methods 
Preparation of h9e peptide solution 
H9e peptide was synthesized at the Bio-Materials and Technology Lab, in the 
Department of Grain Science and Industry at Kansas State University. After synthesis the peptide 
was cleaved, washed with anhydrous ether, dissolved in acetonitrile and distilled water (1:1 
ratio), frozen at -80°C, and freeze dried. Stock solution of peptide solution was made by 
dissolving freeze-dried peptide in 100mM NaHCO3 to 5% wt. Solution was autoclaved before 
use. The purity of the h9e peptide used was ≥ 85% confirmed by high performance liquid 
chromatography (HPLC).  
 
Rheological analysis of instantaneous gelation performance  
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A time sweep was conducted on 5% wt. h9e peptide solution, whole rat blood, and 
antibacterial solution (either 10% ampicillin or 10% neomycin sulfate). Samples were mixed at 
different ratios to yield a total sample size of approximately 400µl. The mixture was 
homogenized and immediately added to the rheometer for evaluation. The elastic modulus, G’, 
of the sample was determined using a C-VOR 150 rheometer (Malvern Instruments, Malvern, 
Worcestershire, United Kingdom). A plate 20mm in diameter was used with 1 % strain and 
frequency of 1 Hz at a 37°C temperature for 30 minutes.  
 
Transmission electron microscopy (TEM) 
The morphology of antibacterial agents and antibacterial agent/h9e mixtures was 
observed using transmission electron microscopy (TEM). Exactly 6 ml of the appropriate sample 
was placed onto a negative glow discharged carbon-coated copper grid for 2 minutes. The 
remaining sample was removed by blotting with kimwipe. The grid was then placed into 2% 
uranyl acetate for 2 min. Extra stain was removed by blotting with tissue paper. The wet grids 
were allowed to air-dry for several minutes prior to being examined under TEM. 
Samples were imaged using a FEI Technai G2transmission electron microscope at an 
electron acceleration voltage of 200 KeV. Images were captured using a standardized, normative 
electron dose and a constant defocus value from the carbon-coated surfaces. The images 
presented are presented in the absence of any further processing or image filtering. 
  
3.3 Preliminary Research Results and Discussion 
3.3.1 Ampicillin 
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The rheological analysis of 5% wt. h9e peptide solution, 10% ampicillin solution, and 
whole rat blood was used to compare the gelation strength at different ratios.  Figure 3.1 shows 
that as the amount of ampicillin added to the mixture decreases, the strength of the gelation 
response slightly increases. Gelation strength is at its highest when ampicillin is not part of the 
mixture, however, small amounts of ampicillin still induce a gelation response. No gelation 
response is formed with ampicillin and h9e solution only.  
 The TEM imaging of ampicillin and 0.5% h9e shows that ampicillin molecules become 
trapped in the h9e fiber matrix (Figure 3.2). At this time the exact mechanism and how it relates 
to a decrease in gel strength is unclear. For the purpose of getting clear images, a very low 
concentration of h9e peptide solution had to be used.  
 
3.3.2 Neomycin sulfate 
The rheological analysis of 5% wt. h9e peptide solution, 10% neomycin sulfate solution, 
and whole rat blood was used to compare the gelation strength.  Figure 3.3 shows that no 
gelation response is formed from this mixture. The figure also shows the vast difference between 
5% h9e only and whole blood gelation response vs the 5% h9e, 10% neomycin, and whole blood 
solution. 
 The TEM imaging of neomycin sulfate and 0.5% h9e shows that neomycin sulfate 
molecules are breaking down and forming thick fibers in the presence of the h9e peptide solution 
(Figure 3.4). The fibers observed, are not h9e fibers. When the fibers are broken, a clean break is 
observed. The fibers formed from the neomycin sulfate and h9e solution are not recovering. The 
fibers appear to form a new substance. It is important to note that during visual examination, the 
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combination of h9e solution and neomycin sulfate solution yield a thick, white substance. For the 
purpose of getting clear images, a very low concentration of h9e peptide solution had to be used.  
 
3.4 Future research suggestions 
1. To determine an appropriate amount of ampicillin or neomycin sulfate that will yield a 
gel forming material that can maintain its antibacterial properties and still induce a 
hemostasis response.  
2. To test the antibacterial ability of the additive with h9e in a manner that will provide 
quick and accurate results.  The Kirby-Bauer disk method used with with a common 
bacterium found in infected wounds, such as Staphylococcus aureus should be sufficient 
for a conceptual study. The ring of inhibition (zone of inhibition) should be measured and 
ring size should be used for comparison and formulation of antibacterial solution.  
3. To determine if there are additional antibacterial agents that will yield a gel forming 
material, can maintain its antibacterial properties and still induce a hemostasis response.   
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Figure 3.1 Storage modulus vs time of 5% wt. h9e peptide solution, 10% ampicillin solution, and 
whole rat blood at various ratios  
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Figure 3.2 TEM imaging of ampicillin only and ampicillin with 0.5% h9e 
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Figure 3.3 Storage modulus vs time of 5% wt. h9e peptide solution, 10% neomycin sulfate 
solution, and whole rat blood (1:1 ratio).   
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Figure 3.4 TEM imaging of neomycin sulfate only and neomycin sulfate with 0.5% h9e  
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